Literature DB >> 14712438

Long-term outcome of renal transplantation in light-chain deposition disease.

Nelson Leung1, Donna J Lager, Morie A Gertz, Kirk Wilson, Sharan Kanakiriya, Fernando C Fervenza.   

Abstract

BACKGROUND: Light-chain deposition disease (LCDD) is a monoclonal gammopathy characterized by nonamyloid deposition of light chain in various organs. A small number of kidney transplantations have been performed on LCDD patients in whom end-stage renal disease (ESRD) developed.
METHODS: The authors retrospectively reviewed the clinical and histologic findings and outcome of 7 patients with LCDD who underwent kidney transplantation at our institution.
RESULTS: Renal insufficiency, hypertension, and proteinuria were present in all 7 patients. Proteinuria level was greater than 3.5 g/24 h in 3 patients. Three patients had microscopic hematuria. Monoclonal protein was detected in the serum in 3 patients, urine in 5, and was undetectable in 2. Median age at presentation was 42.7 (range, 33 to 58) years. The most common renal biopsy findings were mesangial expansion, mesangial nodules, tubular basement membrane thickening, and tubular atrophy. Kappa light chain was detected in all 7 renal biopsy results. Five patients were on dialysis before transplantation. LCDD recurred after a median of 33.3 (range, 2 to 45) months in 5 of the 7 patients. One patient remains on dialysis, whereas the other 4 have died. One patient died of progression of multiple myeloma 3 months after kidney transplantation without evidence of recurrence. Only 1 patient remains recurrence free after 13 years with normal renal allograft function.
CONCLUSION: Although long-term benefits are occasionally seen, renal allograft survival is reduced significantly in LCDD patients. Kidney transplantation should not be an option for LCDD patients unless measures have been taken to reduce light chain production.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14712438     DOI: 10.1053/j.ajkd.2003.09.020

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  38 in total

Review 1.  The pathogenesis and diagnosis of acute kidney injury in multiple myeloma.

Authors:  Colin A Hutchison; Vecihi Batuman; Judith Behrens; Frank Bridoux; Christophe Sirac; Angela Dispenzieri; Guillermo A Herrera; Helen Lachmann; Paul W Sanders
Journal:  Nat Rev Nephrol       Date:  2011-11-01       Impact factor: 28.314

2.  Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease.

Authors:  Camille Cohen; Bruno Royer; Vincent Javaugue; Raphael Szalat; Khalil El Karoui; Alexis Caulier; Bertrand Knebelmann; Arnaud Jaccard; Sylvie Chevret; Guy Touchard; Jean-Paul Fermand; Bertrand Arnulf; Frank Bridoux
Journal:  Kidney Int       Date:  2015-07-15       Impact factor: 10.612

Review 3.  Pathophysiology and management of monoclonal gammopathy of renal significance.

Authors:  Ankur Jain; Richard Haynes; Jaimal Kothari; Akhil Khera; Maria Soares; Karthik Ramasamy
Journal:  Blood Adv       Date:  2019-08-13

4.  Natural history and outcome of light chain deposition disease.

Authors:  Rabya H Sayed; Ashutosh D Wechalekar; Janet A Gilbertson; Paul Bass; Shameem Mahmood; Sajitha Sachchithanantham; Marianna Fontana; Ketna Patel; Carol J Whelan; Helen J Lachmann; Philip N Hawkins; Julian D Gillmore
Journal:  Blood       Date:  2015-09-21       Impact factor: 22.113

5.  Hypertension, renal failure, and edema in a 38-year-old man: light chain deposition disease; a case report and review of the literature.

Authors:  Sarmad Said; Chad J Cooper; Azikiwe C Nwosu; Jorge E Bilbao; German T Hernandez
Journal:  J Nephropathol       Date:  2014-04-01

6.  Paraprotein-Related Kidney Disease: Diagnosing and Treating Monoclonal Gammopathy of Renal Significance.

Authors:  Mitchell H Rosner; Amaka Edeani; Motoko Yanagita; Ilya G Glezerman; Nelson Leung
Journal:  Clin J Am Soc Nephrol       Date:  2016-08-15       Impact factor: 8.237

Review 7.  Deposition-associated diseases related with a monoclonal compound.

Authors:  M J Molina-Garrido; C Guillén-Ponce; A Mora; M Guirado-Risueño; M A Molina; M J Molina; A Carrato
Journal:  Clin Transl Oncol       Date:  2007-12       Impact factor: 3.405

8.  State-of-the-Art Management of Complications of Myeloma and Its Treatment.

Authors:  Monique A Hartley-Brown; Daniel M Sullivan; Rachid Baz
Journal:  Adv Hematol       Date:  2010-06-27

Review 9.  Dysproteinemias and Glomerular Disease.

Authors:  Nelson Leung; Maria E Drosou; Samih H Nasr
Journal:  Clin J Am Soc Nephrol       Date:  2017-11-07       Impact factor: 8.237

Review 10.  Kidney disease and multiple myeloma.

Authors:  Eliot C Heher; Helmut G Rennke; Jacob P Laubach; Paul G Richardson
Journal:  Clin J Am Soc Nephrol       Date:  2013-07-18       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.